Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study
Abstract During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-06750-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402677813837824 |
|---|---|
| author | Tim D. A. Swaab Robert A. Pol Meindert J. Crop Jan-Stephan F. Sanders Stefan P. Berger Hendrik S. Hofker Stephan J. L. Bakker Charlotte A. te Velde-Keyzer |
| author_facet | Tim D. A. Swaab Robert A. Pol Meindert J. Crop Jan-Stephan F. Sanders Stefan P. Berger Hendrik S. Hofker Stephan J. L. Bakker Charlotte A. te Velde-Keyzer |
| author_sort | Tim D. A. Swaab |
| collection | DOAJ |
| description | Abstract During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this change on 1 year post-transplantation outcomes. Thirty-six adult patients who underwent SPK transplantation between June 2015 and June 2023 were included, of whom 21 before February 2020 (ALEM) and 15 after February 2020 (IL2R). Patients were stratified into two groups based on the induction therapy received. One death occurred during the follow up period. A total of three pancreas and two kidney grafts were lost. No differences between kidney and pancreas graft function or rejection rates were observed. Patients receiving IL2R induction had significantly lower 30 day postoperative complication rates (34 vs. 46%, p = 0.03) and experienced fewer bacterial infections (< 6 months: 47 vs. 81%, p = 0.03). Additionally, lower rates of viral (including CMV) and fungal infections were observed. IL2R patients also had a significantly shorter hospital admission durations (14 vs. 30 days, p < 0.001). In conclusion, IL2R induction in SPK recipients was associated with similar short-term graft function and potentially improved outcomes compared to ALEM, warranting cautious interpretation due to sample size. |
| format | Article |
| id | doaj-art-5acd03117bf04eecbf5e0ac1d7f1f968 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-5acd03117bf04eecbf5e0ac1d7f1f9682025-08-20T03:37:29ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-06750-yShort-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective studyTim D. A. Swaab0Robert A. Pol1Meindert J. Crop2Jan-Stephan F. Sanders3Stefan P. Berger4Hendrik S. Hofker5Stephan J. L. Bakker6Charlotte A. te Velde-Keyzer7Department of Surgery, Division of Organ Donation and Transplantation, University Medical Center Groningen, University of GroningenDepartment of Surgery, Division of Organ Donation and Transplantation, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Surgery, Division of Organ Donation and Transplantation, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of GroningenAbstract During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this change on 1 year post-transplantation outcomes. Thirty-six adult patients who underwent SPK transplantation between June 2015 and June 2023 were included, of whom 21 before February 2020 (ALEM) and 15 after February 2020 (IL2R). Patients were stratified into two groups based on the induction therapy received. One death occurred during the follow up period. A total of three pancreas and two kidney grafts were lost. No differences between kidney and pancreas graft function or rejection rates were observed. Patients receiving IL2R induction had significantly lower 30 day postoperative complication rates (34 vs. 46%, p = 0.03) and experienced fewer bacterial infections (< 6 months: 47 vs. 81%, p = 0.03). Additionally, lower rates of viral (including CMV) and fungal infections were observed. IL2R patients also had a significantly shorter hospital admission durations (14 vs. 30 days, p < 0.001). In conclusion, IL2R induction in SPK recipients was associated with similar short-term graft function and potentially improved outcomes compared to ALEM, warranting cautious interpretation due to sample size.https://doi.org/10.1038/s41598-025-06750-yPancreas transplantationImmunosuppressionInductionAlemtuzumabBasiliximabCOVID-19 |
| spellingShingle | Tim D. A. Swaab Robert A. Pol Meindert J. Crop Jan-Stephan F. Sanders Stefan P. Berger Hendrik S. Hofker Stephan J. L. Bakker Charlotte A. te Velde-Keyzer Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study Scientific Reports Pancreas transplantation Immunosuppression Induction Alemtuzumab Basiliximab COVID-19 |
| title | Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study |
| title_full | Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study |
| title_fullStr | Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study |
| title_full_unstemmed | Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study |
| title_short | Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study |
| title_sort | short term outcome after simultaneous pancreas kidney transplantation with alemtuzumab vs basiliximab induction a single center retrospective study |
| topic | Pancreas transplantation Immunosuppression Induction Alemtuzumab Basiliximab COVID-19 |
| url | https://doi.org/10.1038/s41598-025-06750-y |
| work_keys_str_mv | AT timdaswaab shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT robertapol shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT meindertjcrop shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT janstephanfsanders shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT stefanpberger shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT hendrikshofker shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT stephanjlbakker shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy AT charlotteateveldekeyzer shorttermoutcomeaftersimultaneouspancreaskidneytransplantationwithalemtuzumabvsbasiliximabinductionasinglecenterretrospectivestudy |